Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-07-05 (pr-inside.com)
Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact ...
Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact ...
Read more
2024-06-25 (canadianinsider.com)
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
The only place for free North American stock rankings incorporating insider commitment. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. Home of the Canadian Insider Club which offers alerts and premium research.
Read more
2024-06-14 (wrbl.com)
BFA Law Notice: Biogen Inc. (Nasdaq: BIIB) Investors that Lost Money on Investment Have the Opportunity to Lead Securities Fraud Lawsuit and are Urged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting https:
Read more
2024-02-01 (arstechnica.com)
Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandal
The move ends a long saga that "ended up doing a lot of actual damage."
Read more
2023-10-23 (reut.rs)
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rheumatoid arthritis drug Actemra, according to a filing on Monday in Massachusetts federal court.
Read more
2023-10-17 (pionline.com)
Companies move to settle ERISA lawsuits in third quarter
During the third quarter of 2023, 58 ERISA-related lawsuits were filed and/or updated. Each event represents the involved parties either reaching a settlement or filing an appeal, or a court decision was made.
Read more
2023-10-11 (bloomberglaw.com)
Biogen Investors Can Proceed With Alzheimer’s Drug Trial Lawsuit
Biogen Inc. investors will have another chance to prove some of their claims that the pharmaceutical company violated federal securities laws in the way it presented data about the efficacy of its expensive Alzheimer’s drug, Aduhelm.
Read more
2023-07-03 (businessnews.gr)
The "Patriarch" of biotechnology Dr. Stelios Papadopoulos for the 5th BSE Healthcare & Life Sciences Meetup - BusinessNews.gr
BSE will have the honor of hosting the "Patriarch" of biotechnology, Dr. Stelios Papadopoulos, Chairman of the Board of the leading American biotechnology company Biogen. One year after the 1st meeting of the Healthcare & Life Sciences group organized by SEV, as part of the initiative...
Read more
2023-06-13 (statnews.com)
Biogen’s boardroom scandal saddles CEO with first crisis
This was supposed to be the new Biogen. Then came another boardroom controversy.
Read more
2023-04-04 (masslawyersweekly.com)
Securities - Fraud - Knowingly
Where a securities fraud complaint has been filed over the failed commercial rollout of an innovative treatment for Alzheimer's disease, the complaint must be dismissed because (1) none of the defendants' 25 allegedly false and misleading statements are actionable under the Private Securities
Read more
2023-03-30 (endpts.com)
Massachusetts judge dismisses lawsuit against Biogen over failed launch of Alzheimer's drug Aduhelm
A Massachusetts federal judge on Wednesday dismissed a class action lawsuit filed by investors against Biogen and several of its current and former executives over the company's failed Alzheimer's drug, Aduhelm (aducanumab).
Read more
2022-10-10 (mondaq.com)
Biogen Settlement Summary
On Monday September 26, the Department of Justice announced a settlement resolving a lawsuit filed by former employee Michael Bawduniak
Read more